BOSTON, March 29, 2023 — The Institute for Protein Innovation (IPI) will host IPI Surfacing, a symposium on cell surface receptor biology, on Thursday, June 15, 2023. The free, day-long event convenes biomedical scientists at the Joseph B. Martin Conference Center at Harvard Medical School. Registration opens today.
Credit: Image by IPI
BOSTON, March 29, 2023 — The Institute for Protein Innovation (IPI) will host IPI Surfacing, a symposium on cell surface receptor biology, on Thursday, June 15, 2023. The free, day-long event convenes biomedical scientists at the Joseph B. Martin Conference Center at Harvard Medical School. Registration opens today.
As its inaugural symposium, IPI Surfacing reflects the Institute’s mission to advance protein science to accelerate research and improve human health. In addition to providing biomedical researchers with protein tools and expertise to help illuminate biological processes and validate promising drug targets, the Institute also aspires to become an educational resource. This conference marks IPI’s first public effort to build and disseminate knowledge among a community of life scientists facing shared challenges.
“Embedded in our mission is the desire to promote the exchange of ideas on how protein science and technology can advance the knowledge of human health and disease,” said Ken Fasman, president and CEO of IPI. “We’re excited to bring together some of the most influential scientists in cell surface receptor biology for all to learn, connect and be inspired.”
IPI Surfacing speakers include:
- Christopher Garcia, Stanford University
- Yvonne Jones, University of Oxford
- Debora Marks, Harvard University
- Andreas Plückthun, University of Zürich
- Junichi Takagi, Osaka University
In addition, Plückthun, Aled Edwards of the University of Toronto and Meghan Rego of the nonprofit plasmid repository Addgene will join a panel on the promise of synthetic antibodies and challenges to universal access.
IPI Surfacing marks a milestone in the Institute’s progress. By harnessing automation and high-throughput processes, IPI is expanding its capacity to develop and produce synthetic antibodies against cell surface receptors and secreted proteins.
“Cell surface receptors are the targets for many drugs, not to mention the gatekeepers of cell signaling,” said Rob Meijers, director of the antibody platform at IPI and a structural biologist. “Understanding the mechanisms by which a cell understands its surroundings holds enormous promise for biomedical research.”
Learn more about IPI Surfacing and register today.
-30-
About the Institute for Protein Innovation
The Institute for Protein Innovation is pioneering a new approach to scientific discovery and collaboration. As a nonprofit, we provide the biomedical research community with synthetic antibodies and deep protein expertise, empowering researchers to unlock the most elusive mysteries of biology. Our mission is to advance protein science to accelerate research and improve human health. For more information, visit proteininnovation.org or follow us on social media, @ipiproteins
